In this video, David Williamson reviews some of his favorite biotech firms. Many analysts have thrown their weight behind Biogen (NASDAQ: BIIB) and its new BG12 drug for multiple sclerosis. However, David favors Gilead (NASDAQ: GILD) over Biogen since Gilead has a larger, more diverse product pipeline. Celgene (NASDAQ: CELG) is the No. 1 biotech in David's opinion since it also has blockbuster drugs but a PEG of less than 1.0. Amgen (NASDAQ: AMGN) is a big company with more products in development than most people realize. Overall, for value and future earnings potential, David likes Celgene the best.
Can Celgene continue to soar?
Every in-the-know biotech investor has an eye on Celgene. Shares have skyrocketed this year as the company outlined a plan to almost triple its profits in only a few years. But should you buy the story Celgene is selling? Make sure you understand the key opportunities and risks facing this company by picking up The Motley Fool's brand-new premium report on Celgene. To claim your copy today, simply click here now.